Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in
accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome
positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib
mesylate (Gleevec).